Evaluación de la fiabilidad de los dispositivos acelerómetros de retroalimentación inmediata en función de la superficie en la que se realice la reanimación cardiopulmonar / Assessment of the reliability of the accelerometers feedback devices depending on the surface on which cardiopulmonary resuscitation is performed

No disponible

Occupational asthma and dermatitis induced by eugenol in a cleaner

No disponible

Profundidad tumoral y variables histopatológicas en el carcinoma epidermoide lingual. Estudio retrospectivo sobre 60 pacientes / Tumoral thickness and histopathological parameters in the squamous cell carcinoma of tongue

I.- Introducción: La profundidad tumoral representa uno de los principales factores pronósticos del carcinoma epidermoide lingual. II.-Objetivos: Verificar si el espesor máximo tumoral se correlaciona con parámetros histopatológicos agresivos.III.-Material y Métodos: -Diseño: Estudio retrospectivo de base hospitalaria (Enero-1990 a Julio-1997) constituido por 60 pacientes afectos de carcinoma escamoso lingual.-Variables: Filiación del paciente, parámetros histopatológicos y profundidad tumoral.-Procedimientos de laboratorio.-Métodos estadísticos: Estadística descriptiva e inferencial (Método Bonferroni, C- Dunnet, Chi-cuadrado y test de Anova).IV.-Resultados: Asociación estadísticamente significativa entre Índice mitótico y profundidad tumoral(14,84;p<0,001).V.-Conclusiones: Profundidad tumoral e Índice mitótico se correlacionan y representan factores de mal pronóstico en el carcinoma epidermoide lingual (AU)

I.-Introduction: The tumoral thickness represents one of the most ominous prognostic factors of the squamouscell carcinoma of tongue. II.-Objectives: To verify if the tumoral thickness is relationated with others aggressive histopathologic parameters.III.-Material and Methods: -Design: A hospital population retrospective study (January-1990 to July-1997) of 60patients affected of carcinoma of tongue.-Variables: Data patients, histopathological parameters and tumoral thickness.-Laboratory procedures. -Stadistic methods: Descriptive and Inferential stadistical: Bonferroni method, C-Dunnet, Chi-square, Anova test…IV.-Results: There is a statistic association between mitotic Index and tumoral thickness (14,84; p<0,001).V.-Conclusions: Depth of invasion and mitotic Index are actually associated prognostic factors in the carcinoma epidermoid of tongue (AU)

Utilidad de la tomografía por emisión de positrones (PET) y biopsia del ganglio centinela (BGC) en el estadiaje cervical N0 del carcinoma epidermoide orofaríngeo / Usefulness of positron emission tomography (PET) and sentinel node biopsy (CNB) to determine the N0 cervical stage of oropharyngeal epidermoid carcinoma

- Introducción: con los métodos diagnósticos actuales, la determinación de metástasis cervicales ocultas (pN0) de carcinoma escamosos orofaríngeo resulta sumamente dificultoso.- Objetivos: el empleo de una nueva técnica diagnóstica evitará la realización innecesaria de disecciones cervicales.- Técnica: proponemos la realización de la identificación mediante linfogammagrafía del ganglio centinela, su posterior evaluación histopatológica y la realización de la tomografía por emisión de positrones (PET) en la evaluación de metástasis cervicales ocultas (pN0) (AU)

Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica.

BACKGROUND: The inhalation of Parietaria judaica pollen is a common cause of allergic respiratory diseases in the Mediterranean area. The objective of this study was to investigate the safety and clinical efficacy of a chemically modified (depigmented and glutaraldehyde-polymerized) vaccine of Parietaria judaica. METHODS AND RESULTS: Thirty patients with a well-documented clinical history of seasonal rhinitis and clinical sensitivity to Parietaria judaica pollen were included in a randomized trial during 12 months. The study was conducted following good clinical practices and appropriate consent forms were signed. Patients were divided into 2 groups of 15 individuals; group A received the modified extract and group C did not receive specific immunotherapy. Any adverse event was recorded to assess safety. Symptom scores, symptomatic medication use and the results of specific nasal challenges (before and after 12 months of treatment) were recorded to evaluate clinical efficacy. The treatment schedule consisted of an incremental phase of 5 injections and a maintenance dosage of 0.5 ml per month. Each patient received 14 injections during this period. All the patients completed the trial and no adverse reactions related to immunotherapy were recorded. A significant difference (p < 0.001) in symptom scores and overall use of symptomatic medication was observed between the two groups, being both scores lower in group A. No significant differences in nasal sensitivity existed before treatment among the 2 groups. However, after 12 months, a significant difference (p < 0.05) was observed only in group A patients, who showed a significant improvement in specific nasal challenges. CONCLUSIONS: Immunotherapy with depigmented and glutaraldehyde-polymerized extract of Parietaria judaica pollen is safe and effective to treat patients with allergic rhinitis and clinical sensitivity to this pollen.

Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica

Background: The inhalation of Parietaria judaica pollen is a common cause of allergic respiratory diseases in the Mediterranean area. The objective of this study was to investigate the safety and clinical efficacy of a chemically modified (depigmented and glutaraldehyde-polymerized) vaccine of Parietaria judaica. Methods and results: Thirty patients with a well-documented clinical history of seasonal rhinitis and clinical sensitivity to Parietaria judaica pollen were included in a randomized trial during 12 months. The study was conducted following good clinical practices and appropriate consent forms were signed. Patients were divided into 2 groups of 15 individuals; group A received the modified extract and group C did not receive specific immunotherapy. Any adverse event was recorded to assess safety. Symptom scores, symptomatic medication use and the results of specific nasal challenges (before and after 12 months of treatment) were recorded to evaluate clinical efficacy. The treatment schedule consisted of an incremental phase of 5 injections and a maintenance dosage of 0.5 ml per month. Each patient received 14 injections during this period. All the patients completed the trial and no adverse reactions related to immunotherapy were recorded. A significant difference (p < 0.001) in symptom scores and overall use of symptomatic medication was observed between the two groups, being both scores lower in group A. No significant differences in nasal sensitivity existed before treatment among the 2 groups. However, after 12 months, a significant difference (p < 0.05) was observed only in group A patients, who showed a significant improvement in specific nasal challenges. Conclusions: Immunotherapy with depigmented and glutaraldehyde-polymerized extract of Parietaria judaica pollen is safe and effective to treat patients with allergic rhinitis and clinical sensitivity to this pollen (AU)

Antecedentes: La inhalación del polen de Parietaria judaica es una causa frecuente de enfermedades respiratorias alérgicas en la región mediterránea. El objetivo de este estudio era investigar la seguridad y la eficacia clínica de una vacuna químicamente modificada (despigmentada y polimerizada con glutaraldehído) de Parietaria judaica. Métodos y resultados: Se incluyó en un estudio aleatorizado de 12 meses de duración a 30 pacientes con historia clínica bien documentada de rinitis estacional y sensibilidad clínica al polen de Parietaria judaica. El estudio se llevó a cabo conforme a las buenas prácticas clínicas y se firmaron los formularios de consentimiento apropiados. Se distribuyó a los pacientes en dos grupos de 15 sujetos; el grupo A recibió el extracto modificaco y el grupo C no recibió inmunoterapia específica. Para evaluar la inocuidad se registraron las reacciones adversas. Para evaluar la eficacia clínica se registraron las puntuaciones de los síntomas, el uso de medicación sintomática y los resultados de pruebas de provocación nasales específicas (antes y después de 12 meses de tratamiento).El régimen de tratamiento consistió en una fase de incremento de 5 inyecciones y una posología de mantenimiento de 0,5 ml al mes. Cada paciente recibió 14 inyecciones durante ese período. Todos los pacientes se sometieron al ensayo completo y no se registraron reacciones adversas relacionadas con la inmunoterapia. Se observó una diferencia significativa (p < 0,001) en las puntuaciones de los síntomas y el uso global de medicación sintomática entre los dos grupos; ambas puntuaciones fueron menores en el grupo A. Antes del tratamiento no se observaron diferencias significativas en la sensibilidad nasal de los dos grupos. Sin embargo, al cabo de 12 meses, se observó una diferencia considerable (p < 0,05) sólo en los pacientes del grupo A, los cuales experimentaron una mejoría significativa en pruebas de provocación nasales específicas. Conclusiones: La inmunoterapia con extracto despigmentado y polimerizado con glutaral de hído de polen de Parietaria judaica es segura y eficaz para tratar a los pacientes con rinitis alérgica y sensibilidad clínica a este polen (AU)